Innoviva Stock Price, News & Analysis (NASDAQ:INVA)

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings or view top-rated stocks.

3 brokerages have issued 12 month target prices for Innoviva's stock. Their INVA share price targets range from $10.00 to $22.50. On average, they expect the company's stock price to reach $15.17 in the next year. This suggests a possible upside of 9.5% from the stock's current price.
View analysts price targets for INVA or view top-rated stocks among Wall Street analysts.

Innoviva's stock was trading at $13.25 on January 1st, 2023. Since then, INVA shares have increased by 4.5% and is now trading at $13.85.
View the best growth stocks for 2023 here.

Innoviva saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 9,610,000 shares, an increase of 7.1% from the October 31st total of 8,970,000 shares. Based on an average trading volume of 668,000 shares, the short-interest ratio is currently 14.4 days. Currently, 15.2% of the shares of the company are short sold.
View Innoviva's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our INVA earnings forecast.

Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.98 EPS for the quarter. The biotechnology company earned $67.26 million during the quarter. Innoviva had a net margin of 17.17% and a trailing twelve-month return on equity of 24.11%.

ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares U.S. Pharmaceuticals ETF (IHE).Harbor Health Care ETF (MEDI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Innoviva's stock is owned by a variety of retail and institutional investors. Top institutional investors include Westfield Capital Management Co. LP (3.19%), Charles Schwab Investment Management Inc. (1.23%), American Century Companies Inc. (1.20%), Bank of New York Mellon Corp (1.12%), Northern Trust Corp (1.13%) and Invesco Ltd. (1.03%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends.

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.